NAMS Menopause Certification Practice
Exam | Questions &Answers with rationales |
latest update
Q1Physiology
Which hormone shows the earliest and most consistent rise during the menopausal
transition?
A. EstradiolB. Luteinizing hormone (LH)C. Follicle-stimulating hormone (FSH)D.
Progesterone
Rationale: FSH rises earliest and most consistently during perimenopause due to
declining inhibin B from diminishing follicular activity. It is the most sensitive
early marker of ovarian aging and menopausal transition.
Q2Physiology
The dominant estrogen in postmenopausal women is:
A. Estradiol (E2)B. Estriol (E3)C. Estrone (E1)D. Equilin
Rationale: After menopause, estrone (E1) becomes the predominant circulating
estrogen, produced primarily through peripheral aromatization of androstenedione
in adipose tissue. Estradiol levels fall dramatically while estrone persists.
Q3Physiology
Inhibin B is primarily secreted by which ovarian cell type?
A. Theca cellsB. Luteal cellsC. Granulosa cellsD. Stromal cells
Rationale: Inhibin B is secreted by granulosa cells of small antral follicles. Its
decline with follicular depletion during the menopausal transition leads to reduced
negative feedback on FSH, causing FSH to rise — an early marker of diminishing
ovarian reserve.
Q4Physiology
The average age of natural menopause in the United States is approximately:
A. 48 yearsB. 51 yearsC. 54 yearsD. 46 years
Rationale: The median age of natural menopause in the US is approximately 51
years (range 40–58). Menopause is defined retrospectively as 12 consecutive
months of amenorrhea without pathological cause.
Q5Physiology
,Which of the following best defines perimenopause?
A. 12 months of amenorrheaB. The period starting with first irregular cycles until
12 months after the final menstrual periodC. Only the 6 months preceding the final
menstrual periodD. Any time FSH is elevated above 30 mIU/mL
Rationale: Perimenopause encompasses the period from the onset of menstrual
irregularity (or other menopausal symptoms) through 12 months after the final
menstrual period. It is the transition period defined by the STRAW+10 staging
system.
Q6Physiology
Premature ovarian insufficiency (POI) is defined as menopause occurring before
age:
A. 45 yearsB. 40 yearsC. 35 yearsD. 50 years
Rationale: Premature ovarian insufficiency (POI) is defined as loss of normal
ovarian function before age 40, characterized by amenorrhea, elevated FSH (>25
mIU/mL on two occasions), and low estradiol. It affects approximately 1% of
women.
Q7Physiology
The zona reticularis of the adrenal gland primarily produces which androgen
important in postmenopausal women?
A. TestosteroneB. DHEA and DHEA-SC. AndrostenedioneD. Dihydrotestosterone
(DHT)
Rationale: The zona reticularis of the adrenal cortex is the primary source of
dehydroepiandrosterone (DHEA) and its sulfate form DHEA-S in postmenopausal
women. These serve as precursors for peripheral conversion to estrogens and
androgens.
Q8Physiology
Which receptor mediates the cardiovascular protective effects of estrogen
including vasodilation?
A. ERα (estrogen receptor alpha)B. ERβ (estrogen receptor beta)C. GPR30
(GPER)D. Androgen receptor
Show rationale
Q9Physiology
GnRH neurons in the hypothalamus receive input from which peptide implicated in
hot flash pathophysiology?
A. Substance PB. Neurokinin B (NKB)C. Neuropeptide YD. Galanin
Q10Physiology
,The thermoneutral zone refers to:
A. Core body temperature at restB. The ambient temperature range where no
thermoregulatory effort is neededC. The hypothalamic set point for sweatingD.
The temperature differential across skin during a hot flash
Rationale: The thermoneutral zone is the ambient temperature range within which
sweating and shivering are not required. In postmenopausal women, estrogen
deficiency narrows this zone, making small temperature fluctuations sufficient to
trigger hot flashes (sweating) or chills.
Q11Vasomotor Symptoms
Hot flashes most commonly occur during which sleep stage?
A. REM sleepB. N1 (light NREM)C. N2 (intermediate NREM)D. N3 (slow-wave
deep sleep)
Rationale: Hot flashes during sleep (night sweats) are most commonly associated
with N2 (stage 2 NREM) sleep. They trigger awakenings, fragment sleep
architecture, and contribute significantly to sleep disturbance and fatigue in
perimenopausal women.
Q12Vasomotor Symptoms
The SWAN study found that vasomotor symptoms lasted a median of how many
years in women who reported them at the final menstrual period?
A. 2 yearsB. 4.5 yearsC. 7.4 yearsD. 10+ years
Rationale: The SWAN (Study of Women's Health Across the Nation) found that
among women with frequent vasomotor symptoms, median duration was 7.4 years
total and 4.5 years after the final menstrual period. Earlier onset in perimenopause
was associated with longer duration.
Q13Vasomotor Symptoms
Which racial/ethnic group has the highest prevalence and longest duration of
vasomotor symptoms according to SWAN?
A. Asian womenB. Hispanic womenC. White womenD. Black women
Rationale: The SWAN study found that Black women reported the highest
prevalence, greatest severity, and longest duration of vasomotor symptoms
compared to White, Hispanic, Asian, and Japanese women. Asian women
generally reported the lowest prevalence.
Q14Vasomotor Symptoms
Fezolinetant is approved for moderate-to-severe vasomotor symptoms and works
by:
, A. Inhibiting serotonin reuptakeB. Blocking neurokinin 3 receptors (NK3R)C.
Activating estrogen receptorsD. Inhibiting norepinephrine reuptake
Rationale: Fezolinetant is a selective NK3 receptor antagonist that blocks the
action of neurokinin B on KNDy neurons in the hypothalamic thermoregulatory
center. It reduces hot flash frequency and severity without hormonal activity and is
an FDA-approved non-hormonal option.
Q15Vasomotor Symptoms
Which of the following antidepressants has FDA approval specifically for
vasomotor symptoms of menopause?
A. FluoxetineB. VenlafaxineC. Paroxetine mesylate (Brisdelle)D. Escitalopram
Rationale: Paroxetine mesylate (Brisdelle, 7.5 mg) is the only FDA-approved non-
hormonal prescription treatment for moderate-to-severe vasomotor symptoms (at
the time of approval). Other SSRIs/SNRIs are used off-label with varying
evidence.
Q16Vasomotor Symptoms
Gabapentin is thought to reduce hot flashes by acting on which receptor/channel?
A. Serotonin 5-HT2A receptorsB. Alpha-2-delta subunit of voltage-gated calcium
channelsC. GABA-A receptorsD. NK3 receptors
Rationale: Gabapentin binds to the α2δ subunit of voltage-gated calcium channels,
reducing calcium influx and neuronal excitability. This likely modulates the
thermoregulatory center and reduces hot flash frequency. Its use for vasomotor
symptoms is off-label.
Q17Vasomotor Symptoms
Which lifestyle modification has the strongest evidence for reducing vasomotor
symptom severity?
A. YogaB. Weight lossC. Cognitive behavioral therapy (CBT)D. Paced respiration
Rationale: CBT has the strongest evidence among behavioral interventions for
reducing the bothersomeness and impact of hot flashes, particularly in breast
cancer survivors. While weight loss, paced respiration, and yoga show some
benefit, CBT has robust RCT data.
Q18Vasomotor Symptoms
A 52-year-old woman reports 12 hot flashes per day severely affecting quality of
life. She had ER+ breast cancer 3 years ago. The most appropriate management is:
A. Systemic estrogen therapyB. VenlafaxineC. PhytoestrogensD. Testosterone
pellets
Exam | Questions &Answers with rationales |
latest update
Q1Physiology
Which hormone shows the earliest and most consistent rise during the menopausal
transition?
A. EstradiolB. Luteinizing hormone (LH)C. Follicle-stimulating hormone (FSH)D.
Progesterone
Rationale: FSH rises earliest and most consistently during perimenopause due to
declining inhibin B from diminishing follicular activity. It is the most sensitive
early marker of ovarian aging and menopausal transition.
Q2Physiology
The dominant estrogen in postmenopausal women is:
A. Estradiol (E2)B. Estriol (E3)C. Estrone (E1)D. Equilin
Rationale: After menopause, estrone (E1) becomes the predominant circulating
estrogen, produced primarily through peripheral aromatization of androstenedione
in adipose tissue. Estradiol levels fall dramatically while estrone persists.
Q3Physiology
Inhibin B is primarily secreted by which ovarian cell type?
A. Theca cellsB. Luteal cellsC. Granulosa cellsD. Stromal cells
Rationale: Inhibin B is secreted by granulosa cells of small antral follicles. Its
decline with follicular depletion during the menopausal transition leads to reduced
negative feedback on FSH, causing FSH to rise — an early marker of diminishing
ovarian reserve.
Q4Physiology
The average age of natural menopause in the United States is approximately:
A. 48 yearsB. 51 yearsC. 54 yearsD. 46 years
Rationale: The median age of natural menopause in the US is approximately 51
years (range 40–58). Menopause is defined retrospectively as 12 consecutive
months of amenorrhea without pathological cause.
Q5Physiology
,Which of the following best defines perimenopause?
A. 12 months of amenorrheaB. The period starting with first irregular cycles until
12 months after the final menstrual periodC. Only the 6 months preceding the final
menstrual periodD. Any time FSH is elevated above 30 mIU/mL
Rationale: Perimenopause encompasses the period from the onset of menstrual
irregularity (or other menopausal symptoms) through 12 months after the final
menstrual period. It is the transition period defined by the STRAW+10 staging
system.
Q6Physiology
Premature ovarian insufficiency (POI) is defined as menopause occurring before
age:
A. 45 yearsB. 40 yearsC. 35 yearsD. 50 years
Rationale: Premature ovarian insufficiency (POI) is defined as loss of normal
ovarian function before age 40, characterized by amenorrhea, elevated FSH (>25
mIU/mL on two occasions), and low estradiol. It affects approximately 1% of
women.
Q7Physiology
The zona reticularis of the adrenal gland primarily produces which androgen
important in postmenopausal women?
A. TestosteroneB. DHEA and DHEA-SC. AndrostenedioneD. Dihydrotestosterone
(DHT)
Rationale: The zona reticularis of the adrenal cortex is the primary source of
dehydroepiandrosterone (DHEA) and its sulfate form DHEA-S in postmenopausal
women. These serve as precursors for peripheral conversion to estrogens and
androgens.
Q8Physiology
Which receptor mediates the cardiovascular protective effects of estrogen
including vasodilation?
A. ERα (estrogen receptor alpha)B. ERβ (estrogen receptor beta)C. GPR30
(GPER)D. Androgen receptor
Show rationale
Q9Physiology
GnRH neurons in the hypothalamus receive input from which peptide implicated in
hot flash pathophysiology?
A. Substance PB. Neurokinin B (NKB)C. Neuropeptide YD. Galanin
Q10Physiology
,The thermoneutral zone refers to:
A. Core body temperature at restB. The ambient temperature range where no
thermoregulatory effort is neededC. The hypothalamic set point for sweatingD.
The temperature differential across skin during a hot flash
Rationale: The thermoneutral zone is the ambient temperature range within which
sweating and shivering are not required. In postmenopausal women, estrogen
deficiency narrows this zone, making small temperature fluctuations sufficient to
trigger hot flashes (sweating) or chills.
Q11Vasomotor Symptoms
Hot flashes most commonly occur during which sleep stage?
A. REM sleepB. N1 (light NREM)C. N2 (intermediate NREM)D. N3 (slow-wave
deep sleep)
Rationale: Hot flashes during sleep (night sweats) are most commonly associated
with N2 (stage 2 NREM) sleep. They trigger awakenings, fragment sleep
architecture, and contribute significantly to sleep disturbance and fatigue in
perimenopausal women.
Q12Vasomotor Symptoms
The SWAN study found that vasomotor symptoms lasted a median of how many
years in women who reported them at the final menstrual period?
A. 2 yearsB. 4.5 yearsC. 7.4 yearsD. 10+ years
Rationale: The SWAN (Study of Women's Health Across the Nation) found that
among women with frequent vasomotor symptoms, median duration was 7.4 years
total and 4.5 years after the final menstrual period. Earlier onset in perimenopause
was associated with longer duration.
Q13Vasomotor Symptoms
Which racial/ethnic group has the highest prevalence and longest duration of
vasomotor symptoms according to SWAN?
A. Asian womenB. Hispanic womenC. White womenD. Black women
Rationale: The SWAN study found that Black women reported the highest
prevalence, greatest severity, and longest duration of vasomotor symptoms
compared to White, Hispanic, Asian, and Japanese women. Asian women
generally reported the lowest prevalence.
Q14Vasomotor Symptoms
Fezolinetant is approved for moderate-to-severe vasomotor symptoms and works
by:
, A. Inhibiting serotonin reuptakeB. Blocking neurokinin 3 receptors (NK3R)C.
Activating estrogen receptorsD. Inhibiting norepinephrine reuptake
Rationale: Fezolinetant is a selective NK3 receptor antagonist that blocks the
action of neurokinin B on KNDy neurons in the hypothalamic thermoregulatory
center. It reduces hot flash frequency and severity without hormonal activity and is
an FDA-approved non-hormonal option.
Q15Vasomotor Symptoms
Which of the following antidepressants has FDA approval specifically for
vasomotor symptoms of menopause?
A. FluoxetineB. VenlafaxineC. Paroxetine mesylate (Brisdelle)D. Escitalopram
Rationale: Paroxetine mesylate (Brisdelle, 7.5 mg) is the only FDA-approved non-
hormonal prescription treatment for moderate-to-severe vasomotor symptoms (at
the time of approval). Other SSRIs/SNRIs are used off-label with varying
evidence.
Q16Vasomotor Symptoms
Gabapentin is thought to reduce hot flashes by acting on which receptor/channel?
A. Serotonin 5-HT2A receptorsB. Alpha-2-delta subunit of voltage-gated calcium
channelsC. GABA-A receptorsD. NK3 receptors
Rationale: Gabapentin binds to the α2δ subunit of voltage-gated calcium channels,
reducing calcium influx and neuronal excitability. This likely modulates the
thermoregulatory center and reduces hot flash frequency. Its use for vasomotor
symptoms is off-label.
Q17Vasomotor Symptoms
Which lifestyle modification has the strongest evidence for reducing vasomotor
symptom severity?
A. YogaB. Weight lossC. Cognitive behavioral therapy (CBT)D. Paced respiration
Rationale: CBT has the strongest evidence among behavioral interventions for
reducing the bothersomeness and impact of hot flashes, particularly in breast
cancer survivors. While weight loss, paced respiration, and yoga show some
benefit, CBT has robust RCT data.
Q18Vasomotor Symptoms
A 52-year-old woman reports 12 hot flashes per day severely affecting quality of
life. She had ER+ breast cancer 3 years ago. The most appropriate management is:
A. Systemic estrogen therapyB. VenlafaxineC. PhytoestrogensD. Testosterone
pellets
